Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients

PCSK9 Biology and Its Role in Atherothrombosis

(2021) Cristina Barale et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia

(2021) Xiaoyue Ge et al.   Biomed Research International

PCSK9 inhibitors in secondary prevention – an opportunity for personalized therapy

(2020) Chase Board et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications

(2020) Antonio V Sterpetti   Current Atherosclerosis Reports

PCSK9 and atherosclerosis: Looking beyond LDL regulation

(2020) Rosetta Ragusa et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association

(2019) Emelia J. Benjamin et al.   CIRCULATION

Inflammatory and Cholesterol Risk in the FOURIER Trial

(2018) Erin A. Bohula et al.   CIRCULATION

Effect of Evolocumab on Coronary Plaque Composition

(2018) Stephen J. Nicholls et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

(2017) Borja Ibanez et al.   EUROPEAN HEART JOURNAL

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

(2017) Robert P Giugliano et al.   LANCET

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program

(2016) Mohamed Abdel-Wahab et al.   EuroIntervention

The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study

(2015) Masanori Taniwaki et al.   EUROPEAN HEART JOURNAL

Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies

(2014) Naif A. M. Almontashiri et al.   PLoS One

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

A Prospective Natural-History Study of Coronary Atherosclerosis

(2011) Gregg W. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET